Latest
18:18
【HBM Holdings(02142.HK): IND Application of HBM7575 for Asthma Treatment Approved by NMPA】NewTimeSpace News: HBM Holdings announced on 15 July that the Investigational New Drug (IND) application for HBM7575, a long-acting bispecific antibody targeting TSLP and an undisclosed target, has been approved by the National Medical Products Administration (NMPA) for the treatment of asthma.
Tag:
HBM Holdings02142.HK